ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Systematic Position Mapping of Split CRISPR-Cas12a Activators Enables Highly Sensitive miRNA Detection and Cancer Cell Stratification.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Amplification-free Cas12a diagnostics with split crRNA enable rapid and programmable target recognition, yet insufficient understanding of DNA activator architecture prevents predictable control over trans-cleavage activity and sensitivity. Here we systematically map over 200 split DNA activator configurations by introducing nicks at every position across both strands. The mapping reveals that target strand nicks suppress activity with position-dependent severity, while non-target strand nicks enhance activity. Guided by these rules, we engineer an optimized split activator pair that achieves attomolar microRNA detection (LOD: 112 aM), ∼480-fold higher sensitivity than intact activators. The enhanced sensitivity supports multiplexed live-cell profiling of five miRNAs for machine learning-based cancer cell stratification, and is further generalized to non-nucleic acid targets, including APE1 enzyme (0.0073 U/L) and HClO (2.37 pM) through position-informed cleavable sites. This work provides a generalizable methodology for engineering CRISPR-Cas12a performance across diagnostic and biosensing applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.